The federal government’s plan to push patented drug prices lower continues to meet with controversy. The changes to the regulations governing the Patented Medicine Prices Review Board (PMPRB) have aroused criticism from patient groups and the pharmaceutical industry, which are concerned that the changes will result in fewer life-saving drugs being available in Canada. Rather than being open to dissenting voices and facilitating a constructive